Doctor's Best Sam-e 200 mg,, DRB-00206, 1
- Product Code: 1567754831-2544
- Availability: In Stock
-
$ 61.90
***** CONDICIONES PARA LA VENTA *****
1.- Tiempo de entrega de 3 a 5 días Hábiles.
2.- Enviamos su compra a cualquier parte del país.
.
.
***** TITULO COMPLETO *****
.
Doctor's Best Sam-e 200 mg,, DRB-00206, 1.
***** DESCRIPCIÓN DEL PRODUCTO *****
.
. Más información del producto Leer más Ampliar FDA Statement *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. **SAM-e with Soloesse Registered. Prevalence of Depression among American adults. Source: CDC. Why Take Doctor’s Best SAMe? Doctor’s Best SAM-e helps replenish your SAM-e levels and promote a healthy mood.* SAM-e (S-Adenosyl-L-Methionine) is naturally produced by your body and helps maintain healthy emotions. Various factors such as diet and aging can cause low levels of SAM-e, leaving you feeling unbalanced and moody. Supplementing with SAM-e: Soloesse Italian SAM-e is processed to yield the highest available percentage of the active pure S,S form which helps mediate biochemical activity in the human body.* SAM-e and Mood and Cognitive Function SAM-e helps facilitate DNA enzymatic actions. These enzymatic actions are required for the healthy conversion of neurotransmitters responsible for healthy emotions, such as serotonin and dopamine. SAM-e also facilitates glutathione usage which improves the body’s antioxidant defense and helps maintain acetylcholine levels necessary for cognitive function.* SAM-e and Joint Function: In clinical trials, SAM-e has been shown to help increase joint comfort and mobility by promoting the synthesis of proteoglycans, essential components of connective tissue.* SAM-e and Liver Function: SAM-e helps support healthy levels of glutathione, a critical antioxidant which helps protect against free radicals. SAM-e acts as a methyl donor in the synthesis and formation of phosphatidylcholine and L-cysteine, both necessary for maintaining liver health.* Leer más What are the benefits of SAM-e? - Helps enhance mood and neural function.* - Helps promote joint comfort and mobility.* - Helps support liver health and detoxification.* Why take SAMe? - SAMe is a biological compound found in every living cell of the human body.* - SAMe is limited to 3 critical metabolic pathways: trans-methylation, trans-sulfuration and amino-propylations pathways. - If your body is not producing enough SAMe, you might feel blue or have trouble sleeping.* How does it work? - S-Adenosyl Methionine (SAM-e) is produced by the body from ATP and the amino acid methionine which is one of the most important methyl donors in the central nervous system. - Methylation (donation of methyl groups) is an essential process in ensuring the proper function of a number of organ systems. - SAM-e is involved in numerous biochemical reactions in tissue including the liver, joints and brain. Leer más Leer más Doctor Best Double Strength SAMe 400 may help promote mood and cognitive health.* SAMe is a ubiquitous molecule present in all cells of the body and biological fluids and serves as the methyl donor in over 35 different methylation reactions.6 SAMe appears uniformly distributed in the brain where it serves as the major donor of methyl groups required in the synthesis of neuronal messengers and membranes.11 In the past three decades, many randomized clinical trials have evaluated the efficacy of SAMe in improving mood and cognitive health against placebo and various popular antidepressants.*7,12,13. Although most of the clinical trials had a small number of participants, outcomes resulted from these trials are very promising presenting SAMe as a potential alternate and/or a therapeutic supplement in promoting mood and cognitive health.*14-19. Doctor Best Double Strength SAMe 400 may help promote joint comfort and mobility.* Since the 1970's, SAMe has been extensively studied for its potential positive effects on joint health after the publishing of an in vitro study describing the synthesis of proteoglycans by human chondrocytes.20,21 From that period, several clinical studies have been conducted to study the efficacy and tolerability of oral SAMe for patients with joint problems to improve joint mobility and comfort.*22,23 Recent scientific studies may provide more information on the role of SAMe in regulating DNA-methylation/demethylation, epigenetic process required in bone health.*19,24. Doctor Best Double Strength SAMe 400 may help support liver function.* SAMe is the principal biological methyl donor and key mediator of glutathione and polyamine synthesis that has a crucial role in many biochemical processes.25 The therapeutic and protective activities of SAMe have been studied for many years and are known to be related to reduced oxidative stress, the maintenance of mitochondrial function, regulation of the cell cycle and inhibition of various mediators that have important roles in liver health. Consequently, many clinical trials have found that SAMe could play a key role in improving liver function and health.*26-31. Pharmacological and clinical studies: A recent study investigated the efficacy on mood health of SAMe co-administered with a selective serotonin reuptake inhibitor (SSRI) that can be used in patients with mood difficulties. The double-blind randomized trial was conducted among 73 participants who were SSRI non-responders: they were provided with either 1600 mg of SAMe daily or a placebo for 6 weeks. Based on the Hamilton Depression Rating Scale response and remission rates, the study concluded that SAMe could be an effective, well-tolerated and safe adjunctive supplement for SSRI non responders to improve mood health.*12. The efficacy of oral SAMe on mood health was evaluated in a double-blind clinical trial. Participants were given either oral SAMe, escitalopram, or placebo for 12 weeks. From the results of this study, they concluded that oral SAMe was an effective agent in improving mood health.*17. Based on the outcomes of a double-blind placebo-controlled trial, SAMe taken orally for up to 1,600 mg daily was found to be safe for human consumption and well tolerated. Compared to placebo group, individuals in the SAMe group exhibited improvement on relevant clinical scales supporting the idea that SAMe supplement could improve mood health.*32-34. The efficacy and tolerability of an oral fixed dose (800 mg) SAMe augmentation was evaluated in patients with poor mood health. The primary outcome measure was the change from baseline in total score on Hamilton Rating Scale for Depression (HAM-D). At 8 weeks, a significant decrease in HAM-D score was observed indicating that SAMe augmentation may be effective in improving mood health.*33. In a small, open-label, randomized study where SAMe (500 mg daily) were given orally with betaine (a "methyl donor" molecule) to patients with mild mood difficulties, it was found that SAMe with betaine group demonstrated noticeable improvement in mood health with better results in terms of score, number of participants in remission and side effects. The study concluded that SAMe could be a good alternative to improve mood health in patients with mild mood difficulties.*35. In a double-blind clinical trial, the tolerability of SAMe and its effect on joint mobility and comfort were studied in individuals to help with joint discomfort. Results showed that the clinical efficacy of SAMe (1,200 mg taken orally daily) concluded that SAMe was beneficial in improving joint mobility and comfort and was also safe and well tolerated by the subjects.*20 A comparable multicenter, randomized, double-blind study found that SAMe (400 mg taken orally three times daily) was as effective in improving joint comfort in patients with joint problems.*36. A randomized double-blind cross-over study was designed to compare the effect of oral SAMe (1,200 mg daily) on joint comfort of the knee for managing joint discomfort. Results showed that SAMe was as effective in improving in functional health and joint comfort.*37. A study was designed to investigate the effects of SAMe (1,200 mg daily orally) in 123 patients in a double-blind, randomized, placebo-controlled, multicenter clinical trial over a 24-month period. The results showed that long-term treatment with SAMe indicated that treatment with SAMe was safe and well tolerated.*38. Positive outcomes were obtained during a controlled, open-label trial that involved 640 participants using doses of SAMe (500-800 mg) given by parenteral route and showed that this route of SAMe administration was well-tolerated and associated with low incidence of side effects.*29. A study was designed to investigate the hepatic protective effect of preoperative parenteral administration of SAMe. Preliminary findings from this study suggested that preoperative administration of SAMe could be a useful and safe tratment.*30. A pilot study was conducted at the University of California, San Diego, to evaluate the efficacy of oral SAMe in improving abdominal discomfort in children with functional abdominal pain. Results obtained from this study demonstrated that oral SAMe (median oral dose was 950-1400 mg daily for 2 months) was efficient in improving abdominal discomfort in children.*8. Scientific References: 1. Fontecave M, Atta M and Mulliez E. S-adenosylmehionine: nothing goes to waste. Trends Bioch Sc. 2004;29:243-249. 2. Lu SC. S-Adenosylmethionine. Int J Biochem Cell Biol. 2000;32:391-395. 3. Olivier R. S-adenosyl-L-methionine (SAM-e) in combination with B-vitamins and amino acids. Original Internist. 2016;23:91. 4. Agnoli A, Andreoli V, Casacchia M, et al.. Effect of S-adenosyl-L-methionine (SAMe) upon depressive symptoms. J Psychiat. Res. 1976;13:43-54. 5. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr. 2002;76:1177S-1182S. 6. Bottiglieri T, Hyland K. S-adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurol Scand. 1994:154;19-26. 7. Papakostas GI, Alpert JE, and Fava M. S-adenosyl-methionine in depression: A comprehensive review of the literature. Curr Psychiatry Rep. 2003;5:460-466. 8. Choi LJ, Huang JS. A pilot study of S-adenosylmethionine in treatment of functional abdominal pain in children. Alternative Therapies in Health and Medicine. 2013;19:61-64. 9. Johnson JG. Therapeutic Review: S-Adenosyl-Methionine. Journal of Exotic Pet Medicine. 2013;22:225. 10. Kuzelicki NK. S-adenosyl methionine in the therapy of depression and other psychiatric disorders. Drug Dev Res. 2016;77:346-356. 11. Clouatre D. S-adenosylmethionine (SAMe): Efffects in depression, osteoarthritis and other disorders. The Original Internist. 2012, June:53-71. 12. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. The American journal of psychiatry. 2010;167:942-948. 13. Papakostas GI, Cassiello CF, Iovieno N. Folates and S-adenosylmethionine for major depressive disorder. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2012;57:406. 14. De Vanna M and Rigamonti R. Oral S-adenosyl-L-methionine in depression. Curr ther res. 1992;52:478-485. 15. Fontanari D, Palma CD, Giorgetti G. and al. Effects of S-adenosyl-L-methionine on cognitive and vigilance functions in the elderly. Curr Ther Res. 1994;55:682-689. 16. Brown RP, Gerbarg P, Bottiglieri T. S-Adenosylmethionine (SAMe) for Depression. Psychiatric Annals. 2002;32:29-44. 17. Sarris J, Papakostas GI, Vitolo O, Fava M, Mischoulon D. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of affective disorders. 2014;164:76-81. 18. Sarris J, Stough C, Bousman C, et al. An adjunctive antidepressant nutraceutical combination in treating major depression: Study protocol, and clinical considerations. Adv Inter Med. 2015;2:49-55. 19. Nishikawa K, Iwamoto Y, Kobayashi Y, et al. DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S-adenosylmethionine-producing metabolic pathway. Nature medicine. 2015;21:281. 20. Harmand M, Vilamitiana J, Maloche E, et al. Effects of S-adenosylmethionine on human articular chondrocyte differentiation. Am J Med. 1987;83:48-54. 21. Di Padova C. S-adenosylmethionine in the treatment of osteoarthritis. Am J Med. 1987;83:60-65. 22. Muller-Fassbender H. Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis. Am J Med. 1987;83:81-83. 23. MacCagno A, Di Giorgio EE, Caston OL, et al. Double-blind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis. Am J Med. 1987;83:72-77. 24. Parashar S, Cheishvili D, Arakelian A, et al. S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications. Cancer Med. 2015;4:732-744. 25. Mato JM, Alvarez L, Ortiz P, et al. S-Adenosylmethionine synthesis: Molecular mechanisms and clinical implications. Pharmacol Ther. 1997;73:265-280. 26. Stramentinoli G. Pharmacologic aspects of S-adenosylmethionine. Am J Med. 1987;83:35-42. 27. Mato JM, Lu SC. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology. 2007;45:1306-1312. 28. Wang SC and Frey PA. S-adenosylmethionine as an oxidant: the radical SAM superfamily. Trends in Biochemical Sciences. 2007;32: 101–110. 29. Fiorelli G. S-Adenosylmethionine in the treatment of intrahepatic cholestasis of chronic liver disease: A field trial. Current Therapeutic Research. 1999;60:335-348. 30. Liu G, Wang W, Jia W, et al. Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection. World Journal of Surgical Oncology. 2014;12:27-27. 31. Guo T, Chang L, Xiao Y, et al. S-Adenosyl-L-Methionine for the Treatment of Chronic Liver Disease: A Systematic Review and Meta-Analysis: e0122124. PLoS One. 2015;10. 32. Green T, Steingart L, Frisch A et al. The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial. Journal of Neural Transmission. 2012;119:1417-1423. 33. Berardis DD, Marini S, Serroni N, et al. S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study. The Scientific World Journal. 2013;2013:1-5. 34. Bambling M, Parham SC, Coulson S. et al. S-adenosylmethionine (SAMe) and magnesium orotate as adjunctives to SSRIs in sub-optimal treatment response of depression in adults: A pilot study. Advances in Integrative Medicine. 2015;2:56-62. 35. Di Pierro F, Settembre R. Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression. International journal of general medicine. 2015;8:73. 36. Kim J, Lee KH, Lee YJ, et al. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: An 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. Clin Ther. 2009;31:2860-2872. 37. Najm WI, Reinsch S, Hoehler F, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. BMC musculoskeletal disorders. 2004;5:6-6. 38. Mato JM, Cámara J, Fernandez P, et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081–9. Leer más . Descripción del producto Tamaño:60 DHA (ácido docosahexaenoico, omega-3) es un bloque de construcción para las membranas celulares que gestionan los procesos de vida. Este nutriente similar a vitaminas y otros derivados metabólicamente de él son vitales para el rendimiento mental, la salud del corazón y los vasos sanguíneos, la visión, la inmunidad y la curación de heridas, y todas las funciones del órgano. El mejor DHA 500 de Calamari se produce a partir de calamar cosechado de manera sostenible, y se destila doble molecularmente para garantizar la pureza. .
1.- Tiempo de entrega de 3 a 5 días Hábiles.
2.- Enviamos su compra a cualquier parte del país.
.
.
***** TITULO COMPLETO *****
.
Doctor's Best Sam-e 200 mg,, DRB-00206, 1.
***** DESCRIPCIÓN DEL PRODUCTO *****
.
. Más información del producto Leer más Ampliar FDA Statement *These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. **SAM-e with Soloesse Registered. Prevalence of Depression among American adults. Source: CDC. Why Take Doctor’s Best SAMe? Doctor’s Best SAM-e helps replenish your SAM-e levels and promote a healthy mood.* SAM-e (S-Adenosyl-L-Methionine) is naturally produced by your body and helps maintain healthy emotions. Various factors such as diet and aging can cause low levels of SAM-e, leaving you feeling unbalanced and moody. Supplementing with SAM-e: Soloesse Italian SAM-e is processed to yield the highest available percentage of the active pure S,S form which helps mediate biochemical activity in the human body.* SAM-e and Mood and Cognitive Function SAM-e helps facilitate DNA enzymatic actions. These enzymatic actions are required for the healthy conversion of neurotransmitters responsible for healthy emotions, such as serotonin and dopamine. SAM-e also facilitates glutathione usage which improves the body’s antioxidant defense and helps maintain acetylcholine levels necessary for cognitive function.* SAM-e and Joint Function: In clinical trials, SAM-e has been shown to help increase joint comfort and mobility by promoting the synthesis of proteoglycans, essential components of connective tissue.* SAM-e and Liver Function: SAM-e helps support healthy levels of glutathione, a critical antioxidant which helps protect against free radicals. SAM-e acts as a methyl donor in the synthesis and formation of phosphatidylcholine and L-cysteine, both necessary for maintaining liver health.* Leer más What are the benefits of SAM-e? - Helps enhance mood and neural function.* - Helps promote joint comfort and mobility.* - Helps support liver health and detoxification.* Why take SAMe? - SAMe is a biological compound found in every living cell of the human body.* - SAMe is limited to 3 critical metabolic pathways: trans-methylation, trans-sulfuration and amino-propylations pathways. - If your body is not producing enough SAMe, you might feel blue or have trouble sleeping.* How does it work? - S-Adenosyl Methionine (SAM-e) is produced by the body from ATP and the amino acid methionine which is one of the most important methyl donors in the central nervous system. - Methylation (donation of methyl groups) is an essential process in ensuring the proper function of a number of organ systems. - SAM-e is involved in numerous biochemical reactions in tissue including the liver, joints and brain. Leer más Leer más Doctor Best Double Strength SAMe 400 may help promote mood and cognitive health.* SAMe is a ubiquitous molecule present in all cells of the body and biological fluids and serves as the methyl donor in over 35 different methylation reactions.6 SAMe appears uniformly distributed in the brain where it serves as the major donor of methyl groups required in the synthesis of neuronal messengers and membranes.11 In the past three decades, many randomized clinical trials have evaluated the efficacy of SAMe in improving mood and cognitive health against placebo and various popular antidepressants.*7,12,13. Although most of the clinical trials had a small number of participants, outcomes resulted from these trials are very promising presenting SAMe as a potential alternate and/or a therapeutic supplement in promoting mood and cognitive health.*14-19. Doctor Best Double Strength SAMe 400 may help promote joint comfort and mobility.* Since the 1970's, SAMe has been extensively studied for its potential positive effects on joint health after the publishing of an in vitro study describing the synthesis of proteoglycans by human chondrocytes.20,21 From that period, several clinical studies have been conducted to study the efficacy and tolerability of oral SAMe for patients with joint problems to improve joint mobility and comfort.*22,23 Recent scientific studies may provide more information on the role of SAMe in regulating DNA-methylation/demethylation, epigenetic process required in bone health.*19,24. Doctor Best Double Strength SAMe 400 may help support liver function.* SAMe is the principal biological methyl donor and key mediator of glutathione and polyamine synthesis that has a crucial role in many biochemical processes.25 The therapeutic and protective activities of SAMe have been studied for many years and are known to be related to reduced oxidative stress, the maintenance of mitochondrial function, regulation of the cell cycle and inhibition of various mediators that have important roles in liver health. Consequently, many clinical trials have found that SAMe could play a key role in improving liver function and health.*26-31. Pharmacological and clinical studies: A recent study investigated the efficacy on mood health of SAMe co-administered with a selective serotonin reuptake inhibitor (SSRI) that can be used in patients with mood difficulties. The double-blind randomized trial was conducted among 73 participants who were SSRI non-responders: they were provided with either 1600 mg of SAMe daily or a placebo for 6 weeks. Based on the Hamilton Depression Rating Scale response and remission rates, the study concluded that SAMe could be an effective, well-tolerated and safe adjunctive supplement for SSRI non responders to improve mood health.*12. The efficacy of oral SAMe on mood health was evaluated in a double-blind clinical trial. Participants were given either oral SAMe, escitalopram, or placebo for 12 weeks. From the results of this study, they concluded that oral SAMe was an effective agent in improving mood health.*17. Based on the outcomes of a double-blind placebo-controlled trial, SAMe taken orally for up to 1,600 mg daily was found to be safe for human consumption and well tolerated. Compared to placebo group, individuals in the SAMe group exhibited improvement on relevant clinical scales supporting the idea that SAMe supplement could improve mood health.*32-34. The efficacy and tolerability of an oral fixed dose (800 mg) SAMe augmentation was evaluated in patients with poor mood health. The primary outcome measure was the change from baseline in total score on Hamilton Rating Scale for Depression (HAM-D). At 8 weeks, a significant decrease in HAM-D score was observed indicating that SAMe augmentation may be effective in improving mood health.*33. In a small, open-label, randomized study where SAMe (500 mg daily) were given orally with betaine (a "methyl donor" molecule) to patients with mild mood difficulties, it was found that SAMe with betaine group demonstrated noticeable improvement in mood health with better results in terms of score, number of participants in remission and side effects. The study concluded that SAMe could be a good alternative to improve mood health in patients with mild mood difficulties.*35. In a double-blind clinical trial, the tolerability of SAMe and its effect on joint mobility and comfort were studied in individuals to help with joint discomfort. Results showed that the clinical efficacy of SAMe (1,200 mg taken orally daily) concluded that SAMe was beneficial in improving joint mobility and comfort and was also safe and well tolerated by the subjects.*20 A comparable multicenter, randomized, double-blind study found that SAMe (400 mg taken orally three times daily) was as effective in improving joint comfort in patients with joint problems.*36. A randomized double-blind cross-over study was designed to compare the effect of oral SAMe (1,200 mg daily) on joint comfort of the knee for managing joint discomfort. Results showed that SAMe was as effective in improving in functional health and joint comfort.*37. A study was designed to investigate the effects of SAMe (1,200 mg daily orally) in 123 patients in a double-blind, randomized, placebo-controlled, multicenter clinical trial over a 24-month period. The results showed that long-term treatment with SAMe indicated that treatment with SAMe was safe and well tolerated.*38. Positive outcomes were obtained during a controlled, open-label trial that involved 640 participants using doses of SAMe (500-800 mg) given by parenteral route and showed that this route of SAMe administration was well-tolerated and associated with low incidence of side effects.*29. A study was designed to investigate the hepatic protective effect of preoperative parenteral administration of SAMe. Preliminary findings from this study suggested that preoperative administration of SAMe could be a useful and safe tratment.*30. A pilot study was conducted at the University of California, San Diego, to evaluate the efficacy of oral SAMe in improving abdominal discomfort in children with functional abdominal pain. Results obtained from this study demonstrated that oral SAMe (median oral dose was 950-1400 mg daily for 2 months) was efficient in improving abdominal discomfort in children.*8. Scientific References: 1. Fontecave M, Atta M and Mulliez E. S-adenosylmehionine: nothing goes to waste. Trends Bioch Sc. 2004;29:243-249. 2. Lu SC. S-Adenosylmethionine. Int J Biochem Cell Biol. 2000;32:391-395. 3. Olivier R. S-adenosyl-L-methionine (SAM-e) in combination with B-vitamins and amino acids. Original Internist. 2016;23:91. 4. Agnoli A, Andreoli V, Casacchia M, et al.. Effect of S-adenosyl-L-methionine (SAMe) upon depressive symptoms. J Psychiat. Res. 1976;13:43-54. 5. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr. 2002;76:1177S-1182S. 6. Bottiglieri T, Hyland K. S-adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurol Scand. 1994:154;19-26. 7. Papakostas GI, Alpert JE, and Fava M. S-adenosyl-methionine in depression: A comprehensive review of the literature. Curr Psychiatry Rep. 2003;5:460-466. 8. Choi LJ, Huang JS. A pilot study of S-adenosylmethionine in treatment of functional abdominal pain in children. Alternative Therapies in Health and Medicine. 2013;19:61-64. 9. Johnson JG. Therapeutic Review: S-Adenosyl-Methionine. Journal of Exotic Pet Medicine. 2013;22:225. 10. Kuzelicki NK. S-adenosyl methionine in the therapy of depression and other psychiatric disorders. Drug Dev Res. 2016;77:346-356. 11. Clouatre D. S-adenosylmethionine (SAMe): Efffects in depression, osteoarthritis and other disorders. The Original Internist. 2012, June:53-71. 12. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. The American journal of psychiatry. 2010;167:942-948. 13. Papakostas GI, Cassiello CF, Iovieno N. Folates and S-adenosylmethionine for major depressive disorder. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2012;57:406. 14. De Vanna M and Rigamonti R. Oral S-adenosyl-L-methionine in depression. Curr ther res. 1992;52:478-485. 15. Fontanari D, Palma CD, Giorgetti G. and al. Effects of S-adenosyl-L-methionine on cognitive and vigilance functions in the elderly. Curr Ther Res. 1994;55:682-689. 16. Brown RP, Gerbarg P, Bottiglieri T. S-Adenosylmethionine (SAMe) for Depression. Psychiatric Annals. 2002;32:29-44. 17. Sarris J, Papakostas GI, Vitolo O, Fava M, Mischoulon D. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. Journal of affective disorders. 2014;164:76-81. 18. Sarris J, Stough C, Bousman C, et al. An adjunctive antidepressant nutraceutical combination in treating major depression: Study protocol, and clinical considerations. Adv Inter Med. 2015;2:49-55. 19. Nishikawa K, Iwamoto Y, Kobayashi Y, et al. DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S-adenosylmethionine-producing metabolic pathway. Nature medicine. 2015;21:281. 20. Harmand M, Vilamitiana J, Maloche E, et al. Effects of S-adenosylmethionine on human articular chondrocyte differentiation. Am J Med. 1987;83:48-54. 21. Di Padova C. S-adenosylmethionine in the treatment of osteoarthritis. Am J Med. 1987;83:60-65. 22. Muller-Fassbender H. Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis. Am J Med. 1987;83:81-83. 23. MacCagno A, Di Giorgio EE, Caston OL, et al. Double-blind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis. Am J Med. 1987;83:72-77. 24. Parashar S, Cheishvili D, Arakelian A, et al. S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications. Cancer Med. 2015;4:732-744. 25. Mato JM, Alvarez L, Ortiz P, et al. S-Adenosylmethionine synthesis: Molecular mechanisms and clinical implications. Pharmacol Ther. 1997;73:265-280. 26. Stramentinoli G. Pharmacologic aspects of S-adenosylmethionine. Am J Med. 1987;83:35-42. 27. Mato JM, Lu SC. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology. 2007;45:1306-1312. 28. Wang SC and Frey PA. S-adenosylmethionine as an oxidant: the radical SAM superfamily. Trends in Biochemical Sciences. 2007;32: 101–110. 29. Fiorelli G. S-Adenosylmethionine in the treatment of intrahepatic cholestasis of chronic liver disease: A field trial. Current Therapeutic Research. 1999;60:335-348. 30. Liu G, Wang W, Jia W, et al. Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection. World Journal of Surgical Oncology. 2014;12:27-27. 31. Guo T, Chang L, Xiao Y, et al. S-Adenosyl-L-Methionine for the Treatment of Chronic Liver Disease: A Systematic Review and Meta-Analysis: e0122124. PLoS One. 2015;10. 32. Green T, Steingart L, Frisch A et al. The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial. Journal of Neural Transmission. 2012;119:1417-1423. 33. Berardis DD, Marini S, Serroni N, et al. S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study. The Scientific World Journal. 2013;2013:1-5. 34. Bambling M, Parham SC, Coulson S. et al. S-adenosylmethionine (SAMe) and magnesium orotate as adjunctives to SSRIs in sub-optimal treatment response of depression in adults: A pilot study. Advances in Integrative Medicine. 2015;2:56-62. 35. Di Pierro F, Settembre R. Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression. International journal of general medicine. 2015;8:73. 36. Kim J, Lee KH, Lee YJ, et al. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: An 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. Clin Ther. 2009;31:2860-2872. 37. Najm WI, Reinsch S, Hoehler F, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. BMC musculoskeletal disorders. 2004;5:6-6. 38. Mato JM, Cámara J, Fernandez P, et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081–9. Leer más . Descripción del producto Tamaño:60 DHA (ácido docosahexaenoico, omega-3) es un bloque de construcción para las membranas celulares que gestionan los procesos de vida. Este nutriente similar a vitaminas y otros derivados metabólicamente de él son vitales para el rendimiento mental, la salud del corazón y los vasos sanguíneos, la visión, la inmunidad y la curación de heridas, y todas las funciones del órgano. El mejor DHA 500 de Calamari se produce a partir de calamar cosechado de manera sostenible, y se destila doble molecularmente para garantizar la pureza. .